Kuvan is an oral small molecule for the treatment of phenylketonuria (PKU) developed in partnership with Merck Serono. The terms of the agreement specify a reduction in royalties owed to BioMarin on Merck Serono sales outside the US and Japan. Based on the structure of the amended agreement, the reduction in royalties cannot exceed an undisclosed cap.
Stephen Aselage, senior vice president, global commercial development of BioMarin, said: “Acquiring rights to Kuvan in Canada allows BioMarin to better coordinate commercialization efforts in the North American market. This agreement with Merck Serono comes at an exciting time for the company and the PKU community after Kuvan was approved in the US last week.”